ArticleLipids in health and disease2025
Fecal Dysosmobacter spp. concentration is linked to plasma lipidome in insulin-resistant individuals with overweight, obesity and metabolic syndrome.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Meat quality and metabolism alterations in broiler driven by selective breeding and their associations with gut microbiota.Food chemistry: X · 2026Article
- First metagenomic analysis of age-associated changes in the gut microbiome among healthy Saudi adults: SAMS pilot study.Frontiers in aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundObesity is reaching epidemic proportions worldwide. This excessive increase of adipose tissue is a risk factor for the development of multiple diseases and premature death. Amongst associated diseases, metabolic syndrome is one of the main comorbidities of obesity. In this context, the gut microbiota has been recognized as both shaping and responding to host energy metabolism. Recently metabolomics has emerged as a powerful tool to capture a snapshot of the metabolites present in a specific tissue, providing new insights into host-microbiota interactions. Integrating metabolomics with gut microbiota studies could help us better understand how specific species impact on host metabolomic profile. Dysosmobacter welbionis has been identified as a promising next generation beneficial bacteria with potential effects on fat mass and glucose metabolism in mice, and fecal Dysosmobacter spp. concentration was inversely correlated to body mass index fasting glucose and plasmatic HbA1c in humans.
methodsConcentration of Dysosmobacter spp. was quantified by qPCR in the stools of insulin resistant overweight/obese participants with a metabolic syndrome and plasma metabolites were analyzed using untargeted metabolomics. Correlations between Dysosmobacter spp. fecal abundance and the 1169 identified plasma metabolites were uncovered using Spearman correlations followed by a false discovery rate correction.
resultsInterestingly, among the detected metabolites, Dysosmobacter spp. was exclusively associated with lipid molecules. Fecal concentration of Dysosmobacter spp. was positively associated with plasmatic levels of five phosphatidylcholines, arachidonate, two monoacylglycerols, twelve diacylglycerols, three lysophosphatidylethanolamines, one phosphatidylinositol and three lysophosphatidylinositols, as well as glycerophosphoethanolamines, glycerophosphatidylcholine and PC(P-16:0). The correlation was particularly interesting with acylcholine and lysophosphatidylcholine metabolites as, respectively, 6/8 and 8/10 detected molecules were positively associated with Dysosmobacter spp.
conclusionThese results suggest that Dysosmobacter spp. plays a specific role in host lipid metabolism. This finding aligns with previous in vivo studies highlighting lipid profile alterations in multiple tissues of mice treated with this bacterium. Further studies are needed to elucidate the underlying mechanisms and assess its potential therapeutic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.